Heparin-platelet factor 4 antibodies in patients presenting to the ED with thrombosis

American Journal of Emergency Medicine

Volumn 25, Issue 3, 2007, Pages 279-284

  Francis, John L ^a   Drexler, Alane ^a   Kathryn Duncan, Mary ^a   Walker, Jamie M ^a   Hursting, Marcie J ^b   Levine, Robert L ^c  

^a FLORIDA HOSPITAL   (United States)

^b Clinical Science Consulting   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANTIBODIES; ANTICOAGULANTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOSIS;

EID: 33847669243     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2006.07.015     Document Type: Article

References (35)

1. Kelton J.G. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 127 2 Suppl (2005) 9S-20S
2. Hirsh J., Heddle N., and Kelton J.G. Treatment of heparin induced thrombocytopenia: a critical review. Arch Intern Med 164 (2004) 361-369
3. Warkentin T.E., Sheppard J.A., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96 (2000) 1703-1708
4. Francis J.L., Palmer G.J., Moroose R., et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75 (2003) 17-22
5. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 126 (2004) 311S-337S
6. Chilver-Stainer L., Lammle B., and Alberio L. Titre of anti-heparin/PF4 antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost 91 (2004) 276-282
7. Alberio L., Kimmerle S., Baumann A., et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 114 (2003) 528-536
8. Zwicker J.L., Uhl L., Huang W.Y., et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2 (2004) 2133-2137
9. Williams R.T., Damaraju L.V., Mascelli M.A., et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107 (2003) 2307-2312
10. Mattioli A.V., Bonetti L., Sternieri S., et al. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital J Heart 1 (2000) 39-42
11. Bennett-Guerrero E., Slaughter T.F., White W.D., et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130 (2005) 1567-1572
12. Risch L., Fischer J.E., Schmugge M., et al. Association of anti-heparin platelet factor 4 antibody levels and thrombosis in pediatric intensive care patients without thrombocytopenia. Blood Coagul Fibrinolysis 14 (2003) 113-116
13. Calaitges J.G., Liem T.K., Spadone D., et al. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg 29 (1999) 779-785
14. Yu A., Jacobson S.H., Bygden A., et al. The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Clin Chem Lab Med 40 (2002) 21-26
15. Nakamoto H., Shimada Y., Kanno T., et al. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial Int 9 Suppl 1 (2005) S2-S7
16. Mureebe L., Coats R.D., Silliman W.R., et al. Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 136 (2004) 848-853
17. Pena de la Vega L., Miller R.S., Benda M.M., et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 80 (2005) 995-1000
18. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
19. Levine R.L., Hursting M.J., and McCollum D. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?. Chest 130 (2006) 681-687
20. Lubenow N., Kempf R., Eichner A., et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122 (2002) 37-42
21. DeEugenio D.L., Ruggiero N., Thomson L.J., et al. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature. Pharmacotherapy 25 (2005) 615-619
22. Rice L., Attisha W.K., Drexler A., et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 136 (2002) 210-215
23. Warkentin T.E., and Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 (2001) 502-506
24. Smythe M.A., Stephens J.L., and Mattson J.C. Delayed-onset heparin-induced thrombocytopenia. Ann Emerg Med 45 (2005) 417-419
25. Levine R.L., Hursting M.J., Drexler A., et al. Heparin-induced thrombocytopenia in the emergency department. Ann Emerg Med 44 (2004) 511-515
26. Warkentin T.E., Sheppard J.I., Moore J.C., et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 146 (2005) 341-346
27. Sheridan D., Carter C., and Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia. Blood 67 (1986) 27-30
28. Warkentin T.E. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Recommendations of the College of American Pathologists. Arch Pathol Lab Med 126 (2002) 1415-1423
29. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121 (2003) 535-555
30. Juhl D., Eichler P., Lubenow N., et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgG, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haemotol 76 (2006) 420-426
31. Amiral A.J., Fischer A., Boyer-Neumann C., et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92 (1996) 954-959
32. Howell M.D., and Powers R.D. Utility of thrombocytopenia as a marker for heparin allergy in adult ED patients. Am J Emerg Med 24 (2006) 268-270
33. Rice L. Heparin-induced thrombocytopenia. Myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 164 (2004) 1961-1964
34. Levine R.L. Finding haystacks full of needles: from Opus to Osler. Chest 127 (2005) 1488-1490
35. Koerber J.M., Smythe M.A., and Szeczesiul J. An evaluation of unfractionated heparin use to assess the magnitude of risk for heparin induced thrombocytopenia. [abstract]. J Thromb Haemost 3 Suppl 1 (2005) 1144